Last10K.com

Actinium Pharmaceuticals, Inc. (ATNM) SEC Filing 10-K Annual report for the fiscal year ending Tuesday, December 31, 2019

SEC Filings

ATNM Valuations

Intrinsic Value
Financial Stability
Financial Ratios
Insider Trades
Manager Portfolios
Notifications

ATNM Annual Reports

ATNM Quarterly Reports

ATNM Corporate News

Actinium Pharmaceuticals, Inc.

HISTORY TOOLS
CIK: 1388320 Ticker: ATNM
Document and Entity Information - USD ($)
12 Months Ended
Dec. 31, 2019
May 07, 2020
Jun. 28, 2019
Document and Entity Information [Abstract]   
Entity Registrant NameActinium Pharmaceuticals, Inc.  
Entity Central Index Key0001388320  
Amendment Flagfalse  
Current Fiscal Year End Date--12-31  
Document Type10-K  
Document Period End DateDec. 31, 2019  
Document Fiscal Period FocusFY  
Document Fiscal Year Focus2019  
Entity Current Reporting StatusYes  
Entity Filer CategoryNon-accelerated Filer  
Entity Shell Companyfalse  
Entity Small Businesstrue  
Entity Emerging Growth Companyfalse  
Entity Common Stock, Shares Outstanding 303,343,699 
Entity File Number000-52446  
Entity Interactive Data CurrentYes  
Entity Incorporation State Country CodeDE  
Entity Public Float  $ 39,794,272
Entity Voluntary FilersNo  
Entity Well-known Seasoned IssuerNo  

View differences made from one year to another to evaluate Actinium Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Actinium Pharmaceuticals, Inc..

Continue

Assess how Actinium Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Actinium Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statement Of Changes In Stockholders' Equity
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations
Commitments And Contingencies
Commitments And Contingencies (Details)
Derivative Liabilities
Derivative Liabilities (Details Textual)
Derivative Liabilities (Details)
Derivative Liabilities (Tables)
Description Of Business And Summary Of Significant Accounting Policies
Description Of Business And Summary Of Significant Accounting Policies (Details 1)
Description Of Business And Summary Of Significant Accounting Policies (Details)
Description Of Business And Summary Of Significant Accounting Policies (Policies)
Description Of Business And Summary Of Significant Accounting Policies (Tables)
Equity
Equity (Details Textual)
Equity (Details)
Equity (Tables)
Income Taxes
Income Taxes (Details 1)
Income Taxes (Details Textual)
Income Taxes (Details)
Income Taxes (Tables)
Leases
Leases (Details Textual)
Leases (Details)
Leases (Details 1)
Leases (Details 2)
Leases (Details 3)
Leases (Details 4)
Leases (Tables)
Prepaid Expenses And Other Current Assets
Prepaid Expenses And Other Current Assets (Details Textual)
Prepaid Expenses And Other Current Assets (Details)
Prepaid Expenses And Other Current Assets (Tables)
Property And Equipment
Property And Equipment (Details 1)
Property And Equipment (Details)
Property And Equipment (Tables)
Subsequent Event (Details)
Subsequent Events

Material Contracts, Statements, Certifications & more

Actinium Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 23.1: Consent Of Marcum Llp.
Exhibit 31.1: Certification
Exhibit 31.2: Certification
Exhibit 32.1: Certification
Exhibit 32.2: Certification
Ticker: ATNM
CIK: 1388320
Form Type: 10-K Annual Report
Accession Number: 0001213900-20-011475
Submitted to the SEC: Fri May 08 2020 5:03:55 PM EST
Accepted by the SEC: Fri May 08 2020
Period: Tuesday, December 31, 2019
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/atnm/0001213900-20-011475.htm